Kanada - inglise - Health Canada

agila jamp canada inc - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents

Armeenia - inglise - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - vinorelbine (vinorelbine tartrate) - concentrate for solution for infusion - 10mg/ml

Armeenia - inglise - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - vinorelbine (vinorelbine tartrate) - concentrate for solution for infusion - 10mg/ml

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - vinorelbine tartrate - capsule, soft - vinorelbine

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - vinorelbine tartrate - capsule, soft - vinorelbine

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml of vinorelbine - concentrate for injection - 10 mg/ml - active: vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml of vinorelbine excipient: water for injection - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first-line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

teva parenteral medicines, inc. - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine 10 mg in 1 ml

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine injection is indicated: -   in combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) -   as a single agent for the treatment of patients with metastatic nsclc none risk summary based on findings from animal studies and its mechanism of action [see clinical pharmacology (12.1)], vinorelbine injection can cause fetal harm when administered to a pregnant woman. available human data are insufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively (see data). advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are

Malta - inglise - Medicines Authority

strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - vinorelbine tartrate - concentrate for solution for infusion - vinorelbine tartrate 10 mg/ml - antineoplastic agents

Malta - inglise - Medicines Authority

strides arcolab international limited unit 4, metro centre, tolpits lane, watford, hertfordshire, wd 189 ss, united kingdom - vinorelbine tartrate - concentrate for solution for infusion - vinorelbine tartrate 10 mg/ml - antineoplastic agents